Tag Archive for: POLB 001

Poolbeg Pharma plc – Notice of Allowance for Significant POLB 001 Patent in United States

/in

Notice of Allowance for Immunomodulator II further strengthens robust intellectual property portfolio 20 March 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has received a Notice of Allowance from the US Patent Office in […]

Read more

Poolbeg Pharma plc – Further Data Confirms POLB 001’s Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)

/in

Market opportunity estimated to be greater than US$1 billion Key highlights –      Efficacy demonstrated in reducing cancer immunotherapy-induced CRS in an in vivo model –      Data strengthens and facilitates the expansion of patent applications for POLB 001 in cancer immunotherapy-induced CRS –      Independent Advisory Board supportive of POLB 001’s potential to both prevent and treat cancer immunotherapy-induced […]

Read more

Poolbeg Pharma – POLB 001 LPS Challenge Trial Data to be Presented at IUIS

/in

POLB 001 – a potential blockbuster immunomodulator 16 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that an abstract highlighting the potential of POLB 001 as a groundbreaking therapy has been accepted for presentation at the 18th International […]

Read more

Poolbeg Pharma plc: POLB 001 patent portfolio strengthened through granting of US patent

/in

Key highlights ·      Patent granted for use of certain p38 MAP kinase inhibitors for the treatment of hypercytokinaemia ·      Allows for use in combination with an antiviral agent ·      Patent enhances the robust IP portfolio protecting Poolbeg’s growing pipeline   8 March 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’),  a leading infectious disease focused biopharmaceutical company, announces that […]

Read more

Poolbeg Pharma: Positive Results from POLB 001 LPS Human Challenge Trial

/in

Strong potential for POLB 001 to be a blockbuster treatment for severe influenza Key Highlights ·      POLB 001 resulted in a highly significant reduction in p38 MAP kinase driven cytokines ·      POLB 001 treatment exhibited a marked reduction in multiple markers of systemic and local inflammation compared with placebo ·    Trial results demonstrate expected utility in severe influenza […]

Read more